Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780143 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
A Phase 1 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00780143 is a Phase 1 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 3 participants.
The verdict
NCT00780143, a Phase 1 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase I/II study to determine the safety, tolerability and to identify the MTD and DLT of Plitidepsin in combination with a fixed dose of Cytarabine in patients with relapsed/refractory leukemia and to determine the response rate of the combination of Plitidepsin with Cytarabine in patients with relapsed/refractory AML treated at the MTD.
Interventions
- DRUG Plitidepsin plus Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780143
The ClinicalTrials.gov registry entry for NCT00780143 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plitidepsin plus Cytarabine is the first listed.
NCT00780143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780143 about?
NCT00780143 is a clinical study titled "Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia". This is a Phase I/II study to determine the safety, tolerability and to identify the MTD and DLT of Plitidepsin in combination with a fixed dose of Cytarabine in patients with relapsed/refractory leukemia and to determine the response rate of the combination of Plitidepsin with Cytarabine in patient...
What is the current status of trial NCT00780143?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2007-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00780143?
The interventions under investigation include: Plitidepsin plus Cytarabine (DRUG).
Who is sponsoring clinical trial NCT00780143?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.